According to a new study, drugs used to treat agitation in people with dementia are less effective than placebo and may even increase mortality.
Led by the University of Plymouth Lancet, The antidepressant mirtazapine, dementia— And probably more related to mortality than no intervention at all.
Excitement is a common symptom of dementia, characterized by inadequate verbal, vocal, or motor activity, often accompanied by physical and verbal aggression. Non-drug patient-centric care is the first intervention to be provided, but if this does not work, clinicians may move to drug-based alternatives. Mirtazapine is routinely prescribed because antipsychotics have been shown to increase mortality in people with dementia, along with other adverse consequences. This study was designed to add to the evidence base for its effectiveness.
Funded by the National Institute for Health Research (NIHR), the study recruited 204 people with or without potential Alzheimer’s disease from 20 locations across the UK, half to mirtazapine and half. Assigned to placebo. The trial was double-blind. In other words, neither the researchers nor the participants knew what they were taking.
The results showed that the mirtazapine group had more excitement after 12 weeks than the control group.In the mirtazapine group (7 people), by the 16th week Control group There is an analysis (only one) that suggests that this was of slight statistical significance.
Professor Sube Banerjee, a senior researcher at the University of Plymouth’s School of Health Executive Dean and professor of dementia, explained why the results are so surprising but important.
“Dementia affects 46 million people worldwide. This number will double in the next 20 years. Poor quality of life is caused by problems such as excitement and affected people We need to find a way to help, “he said.
“This study shows that common methods of managing symptoms are useless and can even be harmful. It is very important to take these results into account, and mirtazapine is dementia. It is no longer used to treat the excitement of people in the world.
“This study added important information to Evidence base, And we look forward to investigating further treatments that may help improve people’s quality of life. “
A complete study entitled “Mirtazapine Study for Excited Behavior in Dementia (SYMBAD): Randomized, Double-Blind, Placebo-Controlled Trial” can be found at. The lancet.
“A Study of Mirtazapine for Excited Behavior in Dementia (SYMBAD): Randomized, Double-Blind, Placebo-Controlled Trial” Lancet (2021). www.thelancet.com/journals/lan… (21) 01210-1 / fulltext
University of Plymouth
Quote: The study states that common antidepressants should not be used to treat people with dementia (21 October 2021) https://medicalxpress.com/news/2021- Obtained October 21, 2021 from 10-common-antidepressant-longer-people-dementia.html
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.
Common antidepressant should no longer be used to treat people with dementia, study says Source link Common antidepressant should no longer be used to treat people with dementia, study says
The post Common antidepressant should no longer be used to treat people with dementia, study says appeared first on California News Times.